Who
David J. Moss
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, INmune Bio; Pres, CEO, Tres, CFO, Secr, Tonix Pharmaceuticals Holding; Director, Pegasi Energy Resources Corporation.
In numbers
- Trades disclosed
- 61
- Buys
- 12
- Sells
- 6
- Bought
- $562K
- Sold
- $587K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 12 Dec 2007
- Last trade
- 2 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune BioBiotechnology | SEC FORM 4 Code M | $13K9,014 at $1.40 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code X | $1,1279,014 at $0.125 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code X | $1,1729,014 at $0.13 | filing |
| 2 Jul 2026filed 7 Jul 2026 | INMB INmune BioBiotechnology | SEC FORM 4 Code M | $13K9,014 at $1.40 | filing |
| 1 Dec 2025filed 2 Dec 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —59,337 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —59,337 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —275,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —70,663 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —70,663 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —160,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —130,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —223,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —223,000 | filing |
| 18 Nov 2025filed 18 Nov 2025 | INMB INmune Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —160,000 | filing |
News
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027INMB · manilatimes.net · 21 Oct 2026INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with UnipharINMB · manilatimes.net · 21 Oct 2026Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)INMB · themarketsdaily.com · 20 Oct 2026Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, MontanaTNXP · matr.net · 12 Oct 2026
0 headlines in the last 90 days name David J. Moss; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.